抗革兰阴性菌新靶标: 脂多糖转运蛋白LptDE及其抑制剂研究进展
Novel antibacterial drug target against Gram-negative bacteria: lipopolysaccharide transport protein LptDE and its inhibitors
-
摘要: 富含脂多糖(lipopolysaccharide, LPS) 的外膜是绝大多数革兰阴性(Gram-negative, G-) 菌生存必需的生物学屏障。LPS转运蛋白(lipopolysaccharide transport protein, Lpt) 复合体LptDE负责LPS转运和外膜组装的最后关键一步, 在G-菌中普遍存在且结构-功能较为保守, 哺乳动物细胞中缺乏同源蛋白, 是颇具开发前景的抗菌新靶标。近10年, LptDE蛋白三维结构的破译为基于此类“非酶”蛋白靶标的药物发现奠定了基础, 首个作用于LptD的拟肽类化合物murepavadin开启了一类新作用机制的抗菌药物研究。本文将总结LptDE的分子特征、结构-功能, 梳理murepavadin等新型拟肽类抗菌药物的研究进展, 以期为相关研究提供参考。Abstract: The outer membrane composed predominantly of lipopolysaccharide (LPS) is an essential biological barrier for most Gram-negative (G-) bacteria. Lipopolysaccharide transport protein (Lpt) complex LptDE is responsible for the critical final stage of LPS transport and outer membrane assembly. The structure and function of LptDE are highly conserved in most G- bacteria but absent in mammalian cells, and thus LptDE complex is regarded as an attractive antibacterial target. In recent 10 years, the deciphering of the three-dimensional structure of LptDE protein facilities the drug discovery based on such "non-enzyme" proteins. Murepavadin, a peptidomimetic compound, was reported to be the first compound able to target LptD, enlightening a new class of antibacterial molecules with novel mechanisms of action. This article is devoted to summarize the molecular characteristics, structure-function of LptDE protein complex and review the development of murepavadin and related peptidomimetic compounds, in order to provide references for relevant researches.
下载: